HCQ for Non Europeans With Mild to Severe UC
The objective of this study is to assess the efficacy of hydroxychloroquine (HCQ) when
combined with Mesalamine in reducing clinical and histologic disease activity in patients who
have active mild to severe Ulcerative Colitis (UC) and also to assess the immunologic...
Age: 18 years - 66+
Gender: All
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
The researchers intend to prospectively study the safety, clinical efficacy and microbial
outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from
pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella
...
Age: 18 - 75 years
Gender: All
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
The researchers intend to prospectively study the safety, clinical efficacy and microbial
outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from
pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella
...
Age: 18 - 75 years
Gender: All
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in
pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will
last about 172 weeks and may include up to 44 visits.
Age: 2 - 19 years
Gender: All
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK)
of tofacitinib in pediatric participants with moderately to severely active UC. In the US and
EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of...
Age: 2 - 17 years
Gender: All
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled tr...
Age: 18 years - 66+
Gender: All
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer
Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the
healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled tr...
Age: 18 years - 66+
Gender: All
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
It is hypothesized that application at 4-week or greater intervals of the human placental
umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer
(DFU) will, with concomitant management of infection, will result in a higher rate o...
Age: 18 years - 66+
Gender: All
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as
maintenance therapy in participants who completed prior 12-week induction study AMAN
(NCT03518086).
Age: 18 - 80 years
Gender: All
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in
participants with moderately to severely active ulcerative colitis (UC) who have had an
inadequate response to, loss of response, or intolerant to conventional or biologic therapy
f...
Age: 18 - 80 years
Gender: All
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
Age: 18 - 80 years
Gender: All
The Mount Sinai Diabetic Foot Ulcer Prospective Trial
The purpose of this study is to evaluate whether placing stent(s) for a blockage in a leg
vein will help improve the healing of diabetic foot ulcers (DFU). The investigators know from
having taken care of many patients with diabetic foot ulcers that it is a major ca...
Age: 30 - 64 years
Gender: All
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients
(age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical
practice. TARGET-IBD will create a research registry of patients with IBD within academic...
Age: 2 years - 66+
Gender: All
PriMatrix for the Management of Diabetic Foot Ulcers
The study will evaluate the efficacy of PriMatrix Dermal Repair Scaffold in the management of diabetic foot ulcers in subjects with diabetes mellitus versus the Standard of Care treatment. Half of patients will be treated using PriMatrix while the other half will receiv...
Age: 18 years - 66+
Gender: All
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in
patients with moderately to severely active UC who are treated as recommended in the product
label.
Age: 18 - 99 years
Gender: All